Por Grace Foundation

Grace Science is a clinical-stage biotechnology company and research foundation dedicated to developing a cure for NGLY1 Deficiency, an ultra-rare genetic disorder. Founded by Matt and Kristen Wilsey following their daughter's diagnosis, the organization operates a unique model that bridges academic research and commercial drug development. Their lead program, GS-100, is an AAV9-based gene therapy designed to deliver a functional NGLY1 gene to patients, and it is currently being evaluated in a Phase 1/2 clinical trial. The company leverages a global network of scientists and clinicians to advance its pipeline and improve the lives of those affected by rare diseases. By integrating patient data with cutting-edge science, Grace Science aims to accelerate the path to effective treatments for rare conditions.